Literature DB >> 17495178

Prostate cancer: body-array versus endorectal coil MR imaging at 3 T--comparison of image quality, localization, and staging performance.

Stijn W T P J Heijmink1, Jurgen J Fütterer, Thomas Hambrock, Satoru Takahashi, Tom W J Scheenen, Henkjan J Huisman, Christina A Hulsbergen-Van de Kaa, Ben C Knipscheer, Lambertus A L M Kiemeney, J Alfred Witjes, Jelle O Barentsz.   

Abstract

PURPOSE: To prospectively compare image quality and accuracy of prostate cancer localization and staging with body-array coil (BAC) versus endorectal coil (ERC) T2-weighted magnetic resonance (MR) imaging at 3 T, with histopathologic findings as the reference standard.
MATERIALS AND METHODS: After institutional review board approval and written informed consent, 46 men underwent 3-T T2-weighted MR imaging with a BAC (voxel size, 0.43 x 0.43 x 4.00 mm) and an ERC (voxel size, 0.26 x 0.26 x 2.50 mm) before radical prostatectomy. Four radiologists independently evaluated data sets obtained with the BAC and ERC separately. Ten image quality characteristics related to prostate cancer localization and staging were assigned scores. Prostate cancer presence was recorded with a five-point probability scale in each of 14 segments that included the whole prostate. Disease stage was classified as organ-confined or locally advanced with a five-point probability scale. Whole-mount-section histopathologic examination was the reference standard. Areas under the receiver operating characteristic curve (AUCs) and diagnostic performance parameters were determined. A difference with a P value of less than .05 was considered significant.
RESULTS: Forty-six patients (mean age, 61 years) were included for analysis. Significantly more motion artifacts were present with ERC imaging (P<.001). All other image quality characteristics improved significantly (P<.001) with ERC imaging. With ERC imaging, the AUC for localization of prostate cancer was significantly increased from 0.62 to 0.68 (P<.001). ERC imaging significantly increased the AUCs for staging, and sensitivity for detection of locally advanced disease by experienced readers was increased from 7% (one of 15) to a range of 73% (11 of 15) to 80% (12 of 15) (P<.05), whereas a high specificity of 97% (30 of 31) to 100% (31 of 31) was maintained. Extracapsular extension as small as 0.5 mm at histopathologic examination could be accurately detected only with ERC imaging.
CONCLUSION: Image quality and localization improved significantly with ERC imaging compared with BAC imaging. For experienced radiologists, the staging performance was significantly better with ERC imaging. (c) RSNA, 2007.

Entities:  

Mesh:

Year:  2007        PMID: 17495178     DOI: 10.1148/radiol.2441060425

Source DB:  PubMed          Journal:  Radiology        ISSN: 0033-8419            Impact factor:   11.105


  87 in total

1.  Prediction of prostate cancer extracapsular extension with high spatial resolution dynamic contrast-enhanced 3-T MRI.

Authors:  B Nicolas Bloch; Elizabeth M Genega; Daniel N Costa; Ivan Pedrosa; Martin P Smith; Herbert Y Kressel; Long Ngo; Martin G Sanda; William C Dewolf; Neil M Rofsky
Journal:  Eur Radiol       Date:  2012-06-03       Impact factor: 5.315

2.  Image registration for targeted MRI-guided transperineal prostate biopsy.

Authors:  Andriy Fedorov; Kemal Tuncali; Fiona M Fennessy; Junichi Tokuda; Nobuhiko Hata; William M Wells; Ron Kikinis; Clare M Tempany
Journal:  J Magn Reson Imaging       Date:  2012-05-29       Impact factor: 4.813

Review 3.  Dynamic contrast-enhanced magnetic resonance imaging and pharmacokinetic models in prostate cancer.

Authors:  Tobias Franiel; Bernd Hamm; Hedvig Hricak
Journal:  Eur Radiol       Date:  2010-12-24       Impact factor: 5.315

4.  Performance of T2 Maps in the Detection of Prostate Cancer.

Authors:  Aritrick Chatterjee; Ajit Devaraj; Melvy Mathew; Teodora Szasz; Tatjana Antic; Gregory S Karczmar; Aytekin Oto
Journal:  Acad Radiol       Date:  2018-05-03       Impact factor: 3.173

5.  [The relevance of magnetic resonance imaging (MRI) for the detection and exclusion of prostate cancer].

Authors:  J Stattaus; M Forsting
Journal:  Urologe A       Date:  2010-03       Impact factor: 0.639

6.  Prospective motion correction using tracking coils.

Authors:  Lei Qin; Ehud J Schmidt; Zion Tsz Ho Tse; Juan Santos; William S Hoge; Clare Tempany-Afdhal; Kim Butts-Pauly; Charles L Dumoulin
Journal:  Magn Reson Med       Date:  2012-05-07       Impact factor: 4.668

7.  The role of magnetic resonance imaging (MRI) in focal therapy for prostate cancer: recommendations from a consensus panel.

Authors:  Berrend G Muller; Jurgen J Fütterer; Rajan T Gupta; Aaron Katz; Alexander Kirkham; John Kurhanewicz; Judd W Moul; Peter A Pinto; Ardeshir R Rastinehad; Cary Robertson; Jean de la Rosette; Rafael Sanchez-Salas; J Stephen Jones; Osamu Ukimura; Sadhna Verma; Hessel Wijkstra; Michael Marberger
Journal:  BJU Int       Date:  2013-11-13       Impact factor: 5.588

8.  Influence of imaging and histological factors on prostate cancer detection and localisation on multiparametric MRI: a prospective study.

Authors:  Flavie Bratan; Emilie Niaf; Christelle Melodelima; Anne Laure Chesnais; Rémi Souchon; Florence Mège-Lechevallier; Marc Colombel; Olivier Rouvière
Journal:  Eur Radiol       Date:  2013-03-15       Impact factor: 5.315

9.  Relationship between T2 relaxation and apparent diffusion coefficient in malignant and non-malignant prostate regions and the effect of peripheral zone fractional volume.

Authors:  C J Simpkin; V A Morgan; S L Giles; S F Riches; C Parker; N M deSouza
Journal:  Br J Radiol       Date:  2013-02-20       Impact factor: 3.039

Review 10.  Role of Multiparametric MR Imaging in Malignancies of the Urogenital Tract.

Authors:  Alberto Diaz de Leon; Daniel Costa; Ivan Pedrosa
Journal:  Magn Reson Imaging Clin N Am       Date:  2016-02       Impact factor: 2.266

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.